A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of Age - Trial NCT06354257
Access comprehensive clinical trial information for NCT06354257 through Pure Global AI's free database. This Phase 1 trial is sponsored by GlaxoSmithKline and is currently Recruiting. The study focuses on Tuberculosis. Target enrollment is 25 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
GlaxoSmithKline
Timeline & Enrollment
Phase 1
Apr 05, 2024
Oct 30, 2024
Primary Outcome
Area under the plasma drug concentration (AUC)-time curve from time zero to extrapolated to infinity (AUC[0-inf]) of EE after being administered with 14 days of GSK3036656 at DL 2,Maximum observed concentration (Cmax) of EE after being administered with 14 days of GSK3036656 at DL 2,AUC(0-inf) of LNG after being administered with 14 days of GSK3036656 at DL 2,Cmax of LNG after being administered with 14 days of GSK3036656 at DL 2
Summary
The purpose of this study is to provide data showing if there are any effects of GSK3036656
 on a combined oral contraceptive containing Ethinyl Estradiol (EE) and Levonorgestrel (LNG),
 which will help inform future studies on suitable contraceptive measures to be used.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06354257
Non-Device Trial